Repligen Corp. (NASDAQ: RGEN) on Friday, soared 6.37% from the previous trading day, before settling in for the closing price of $132.36. Within the past 52 weeks, RGEN’s price has moved between $110.45 and $211.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 31.42%. The company achieved an average annual earnings per share of -17.24%. With a float of $51.96 million, this company’s outstanding shares have now reached $55.77 million.
Let’s determine the extent of company efficiency that accounts for 1783 employees.
Repligen Corp. (RGEN) Breakdown of a Key Holders of the stock
Observing investor behavior towards Medical Instruments & Supplies industry stocks is more important than anything else. The insider ownership of Repligen Corp. is 7.01%, while institutional ownership is 102.31%. The most recent insider transaction that took place on Jun 14 ’24, was worth 248,160. In this transaction Chief Executive Officer of this company bought 2,000 shares at a rate of $124.08, taking the stock ownership to the 165,177 shares. Before that another transaction happened on Jun 14 ’24, when Company’s Director bought 1,615 for $124.94, making the entire transaction worth $201,776. This insider now owns 4,613 shares in total.
Repligen Corp. (RGEN) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -17.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 17.05% during the next five years compared to 15.08% growth over the previous five years of trading.
Repligen Corp. (NASDAQ: RGEN) Trading Performance Indicators
Repligen Corp. (RGEN) is currently performing well based on its current performance indicators. A quick ratio of 5.24 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.95. Likewise, its price to free cash flow for the trailing twelve months is 71.82.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.25, a number that is poised to hit 0.33 in the next quarter and is forecasted to reach 1.99 in one year’s time.
Technical Analysis of Repligen Corp. (RGEN)
Looking closely at Repligen Corp. (NASDAQ: RGEN), its last 5-days average volume was 0.83 million, which is a jump from its year-to-date volume of 0.61 million. As of the previous 9 days, the stock’s Stochastic %D was 66.09%. Additionally, its Average True Range was 7.02.
During the past 100 days, Repligen Corp.’s (RGEN) raw stochastic average was set at 30.45%, which indicates a significant decrease from 88.58% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.36% in the past 14 days, which was higher than the 44.80% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $137.81, while its 200-day Moving Average is $163.92. However, in the short run, Repligen Corp.’s stock first resistance to watch stands at $144.93. Second resistance stands at $149.06. The third major resistance level sits at $154.35. If the price goes on to break the first support level at $135.50, it is likely to go to the next support level at $130.21. Now, if the price goes above the second support level, the third support stands at $126.08.
Repligen Corp. (NASDAQ: RGEN) Key Stats
Market capitalization of the company is 7.87 billion based on 55,876K outstanding shares. Right now, sales total 638,760 K and income totals 41,580 K. The company made 151,350 K in profit during its latest quarter, and 2,090 K in sales during its previous quarter.
